Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2025 | ARTO: impact of BRCA status in abiraterone-treated mCRPC ± SBRT

Giulio Francolini • 14 Feb 2025

GU Cancers 2025

ARTO

Giulio Francolini, MD, University of Florence, Florence, Italy, explores a secondary analysis from the Phase II ARTO trial (NCT03449719), which assessed the impact of BRCA status on outcomes in patients with oligometastatic castration-resistant prostate cancer treated with abiraterone with or without stereotactic body radiotherapy (SBRT). The findings confirm a benefit of SBRT in BRCA-negative and untested patients, while results in BRCA-positive patients remain inconclusive due to limited sample size. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.